[Chronic liver diseases and diabetes].

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Chronic liver diseases can exacerbate insulin resistance, increasing diabetes risk.
• Diabetes, particularly with obesity and dyslipidemia, contributes to nonalcoholic fatty liver disease (NAFLD) progression.
• Existing antidiabetic therapies may be limited by the severity of liver dysfunction.

Purpose of the Study:

• To review the complex interplay between diabetes and chronic liver disease.
• To outline how antidiabetic treatment strategies should be adapted based on liver disease severity.
• To discuss the indications and limitations of various antidiabetic drug classes in liver disease patients.

Main Methods:

• Literature review of studies on diabetes and chronic liver disease.
• Analysis of the impact of liver disease on glucose metabolism and insulin sensitivity.
• Evaluation of antidiabetic medication safety and efficacy across different stages of liver damage.

Main Results:

• Chronic liver disease necessitates individualized antidiabetic drug selection.
• Diabetes is a risk factor for NAFLD and its progression to cirrhosis and hepatocellular carcinoma.
• Specific antidiabetic agents have varying safety profiles depending on the degree of hepatic impairment.

Conclusions:

• Antidiabetic treatment must be carefully adjusted according to liver disease stage.
• Understanding the bidirectional relationship between diabetes and liver disease is crucial for patient management.
• Further research is needed to optimize pharmacotherapy for diabetic patients with chronic liver conditions.